Weight-loss drugmaker Novo Nordisk invests $1.2 bn in new factory in Denmark
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was investing 8.5 billion kroner ($1.2 billion) to build a new factory in Denmark to produce drugs against rare diseases.
Barron's on MSN1h
Novo’s New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way.The end of Novo Nordisk’s supply problems could bring new headaches for ... Novo says that it has regulatory clearance ...
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular ...
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both Wegovy and Ozempic) and other drug manufacturers have invested heavily ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...
Novo Nordisk currently controls approximately 55% of shares in the diabetes and obesity market through drugs like Ozempic ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...
3don MSN
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback